Introduction
Multiple myeloma (MM) is a plasma cell proliferative disorder characterized by the accumulation of clonal plasma cells predominantly in the bone marrow with tumor cells present only in small numbers in the peripheral blood. 1, 2 This disease remains incurable despite high-dose chemotherapy and stem cell transplant or treatment with any of the newly introduced therapies such as thalidomide and its analogs as well as the proteasome inhibitor Velcade. 3 New therapies based on better understanding of the disease biology are urgently needed.
The malignant plasma cells in MM exhibit a relatively low proliferation rate as well as a low rate of apoptosis. 4, 5 Although the mechanisms behind the reduced apoptotic rates of malignant plasma cells are not fully understood, the aberrant expression of various antiapoptotic proteins has been implicated. Elevated expression of the antiapoptotic Bcl-2 family members Bcl-2 and Bcl-xL has been reported in MM cell lines and primary patient samples and may be correlated with resistance to therapy as well as disease stage. [6] [7] [8] Studies have indicated that increased expression of Bcl-2 provides resistance to therapy with interferon, dexamethasone, etoposide, doxorubicin and bortezomib, [9] [10] [11] [12] and overexpression of Bcl-xL in MM cell lines leads to increased resistance to doxorubicin and melphalan, which are commonly used for MM treatment. 13 These findings are consistent with a study describing increased expression of Bcl-xL in plasma cells of relapsed MM patients. 14 Overexpression of Bcl-2 along with abnormal expression of oncogenes such as c-Myc has been associated with development of plasmacytomas in mice. 15 Transgenic mice overexpressing a Bcl-xL transgene in mature B cells and plasma cells develop nonmalignant accumulation of plasma cells, whereas coexpression of Bcl-xL and c-Myc leads to development of aggressive plasma cell malignancies. 16 Together, these findings raise the possibility that inhibition of Bcl-2 family protein function may abrogate the survival effect that is bestowed upon MM cells by antiapoptotic molecules and elicit programmed cell death of the malignant plasma cells.
ABT-737 is a small-molecule inhibitor designed to specifically inhibit antiapoptotic proteins of the Bcl-2 family. 17, 18 The development of this molecule is the result of a high-throughput chemical library nuclear magnetic resonance (NMR) screen and additional chemical modification to minimize binding to serum albumin and enhance the therapeutic potential of the drug. This molecule is a BH3 (Bcl-2 homology region 3) mimetic that binds with high affinity to Bcl-xL, Bcl-2 and Bcl-w. Binding of ABT-737 to a hydrophobic groove on Bcl-2 family proteins prevents binding of Bax, tilting the balance of pro-and antiapoptotic molecules in favor of cellular apoptosis. Use of this small molecule alone or in combination could potentially be a potent therapeutic approach for plasma cell malignancies. We have examined the in vitro activity of this compound and its mechanisms in the context of MM to assess the potential for future clinical evaluation. Here we demonstrate the potent antimyeloma activity of ABT-737 using several MM cell lines as well as primary patient cells. Initiation of apoptotic pathways and cleavage of effector caspases are clearly preceded by changes in the Bax/Bcl-2 ratio and disruption of the mitochondrial membrane integrity. We confirm the ability of ABT-737 to disrupt critical survival and proliferation signals in the MM cells inducing cell death even in the presence of marrow stromal cells. These results form the framework for future clinical evaluation of this drug in patients with MM. University, Chicago, IL, USA), doxorubicin-resistant (Dox40), melphalan-resistant (LR5) RPMI 8226 and sensitive RPMI 8226 human MM cell lines (Dr William Dalton, Moffitt Cancer Center, Tampa, FL, USA), OPM-1 and OPM-2 human MM cells (Dr Leif Bergsagel, Mayo Clinic, Scottsdale, AZ, USA) were all cultured in RPMI 1640 medium (Sigma Chemical, St Louis, MO, USA) supplemented with 10% fetal bovine serum, 2 mM Lglutamine (GIBCO, Grand Island, NY, USA), 100 U/ml penicillin and 100 mg/ml streptomycin (medium A). KAS-6/1 and ANBL-6 MM cells (Dr Diane Jelinek, Mayo Clinic, Rochester, MN, USA) were grown in medium A supplemented with 1 ng/ml interleukin-6 (IL-6).
Materials and methods

MM cell lines, patient cells and marrow stromal cells
Bone marrow (BM) aspirates from patients with MM were obtained after informed consent under a protocol reviewed and approved by the Mayo Foundation Institutional Review Board in accordance with the Declaration of Helsinki and the applicable federal regulations. The samples were ACK lysed to remove the red cells, and MM cells were separated by positive selection with CD138 antibodies conjugated to magnetic beads using a RoboSep (StemCell Technologies, Vancouver, BC, Canada) cell separation device. The isolated MM cells were checked for purity using a slide-based method to confirm more than 95% purity. MM cells were placed in medium A for use in the respective assays.
For the generation of bone marrow stromal cells (BMSCs), CD138-negative MNCs were placed in 25-mm 2 culture flasks in RPMI 1640 medium containing 20% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin. For the experiments, BMSCs were incubated in 96-well culture plates (approximately 5000-10 000 BMSCs/well) for 24 h or grown to confluence in six-well plates as required for individual experiments. 19, 20 
ABT-737
The BH3 mimetic ABT-737 was obtained from Abbott Laboratories, (Abbott Park, IL, USA) ABT-737 was dissolved in dimethylsulfoxide and stored at À201C until use to avoid repeated freeze-thaw.
Cellular viability and cell proliferation assays
MM cell lines (3-5 Â 10 4 cells per well) were incubated in flatbottomed 96-well culture plates in medium A for the indicated time periods and pulsed with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT; Chemicon International Inc., Temecula, CA, USA) for 4 h at 371C. After adding isopropanol containing 0.06 N HCl, the absorbance at 570 nm (subtracting the background at 630 nm) was measured using a spectrophotometer (Molecular Devices, Sunnyvale, CA, USA). Cells were incubated with the indicated concentrations of ABT-737 for 48 h to measure dose-dependent effects upon viability. All experiments were performed in triplicate and each assay was repeated on three different occasions for confirmation.
Growth factor impact upon ABT-737-mediated cytotoxicity was examined by adding recombinant IL-6 (10 ng/ml), insulinlike growth factor 1 (IGF-1; 50 ng/ml) or vascular endothelial growth factor (VEGF; 25 ng/ml; all cytokines were obtained from R&D Systems, Minneapolis, MN, USA). Studies with combinations of bortezomib (1-4 nM) and melphalan (1-7 mM) were similarly performed in 24-h cultures, and cytotoxicity was determined using the MTT assay.
For experiments using cocultures of MM cells with BMSCs, DNA synthesis was measured by tritiated thymidine uptake ( 3 H-TdR; Perkin-Elmer, Boston, MA, USA) as described previously. 19, 20 BMSCs were plated onto flat-bottomed 96-well plates at a concentration of 5-10 000 cells per well and allowed to adhere overnight. MM cells (2-3 Â 10 4 cells/well) were added to the wells in the presence of medium alone or ABT-737 and incubated for 48 h at 371C. Cells were pulsed with 3 H-TdR (0.5 mCi/well; 0.0185 MBq) during the last 8 h of 48-h cultures, harvested on glass fiber filters using a Combi cell harvester (Molecular Devices, Sunnyvale, CA, USA) and counted using a Beckman LS6000SC scintillation counter (Beckman Coulter Inc., Fullerton, CA, USA). All experiments were performed in triplicate.
Measurement of apoptosis in MM cell lines
MM cell lines were cultured in six-well plates as described, washed and resuspended in annexin binding buffer (10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid pH 7.4, 140 mM NaCl, 2.5 mM CaCl 2 ) after which Annexin V-FITC (CALTAG, Burlingame, CA, USA) was added and incubated for 15 min at 41C. After washing with annexin binding buffer, cells were resuspended in buffer containing propidium iodide (PI) (Sigma Chemical). Flow cytometry was performed using a FACSCanto (BD Biosciences, San Jose, CA, USA). Levels of caspase 3, 8 and 9 were indirectly determined by the production of FL1 fluorescence by cleaved substrate using reagents from OncoImmunin (Gaithersburg, MD, USA). PhiPhiLux G1D2 (catalog no. A304R1G-3) was used for the detection of caspase 3, while CaspaLux 8 L1D2 (catalog no. CPL8R1L-3) and CaspaLux 9 M1D2 (catalog no. CPL9R1M-3) were used for the detection of caspases 8 and 9.
Measurement of apoptosis in MM patient cells using Apo 2.7
Cells were cultured in RPMI 1640 media containing 20% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 ug/ml streptomycin in 24-well plates. CD38-APC (BD Biosciences), CD45-PERCP (BD Biosciences) and either IgG1-PE (BD Biosciences) or Apo 2.7-PE (Immunotech, Fullerton, CA, USA) were added to cells and analyzed on the BD FACSCanto. Plasma cells were identified by their characteristic CD38/CD45 staining pattern and the Apo 2.7 staining was analyzed for the entire plasma cell population and subsets. CD138 selected plasma cells were treated in a similar manner and the percentage of Apo 2.7 cells was determined by flow cytometry following 36-48 h of incubation.
Measurement of Bax/Bcl-2 ratio
MM cells were cultured as described previously in six-well plates with or without ABT-737 (10 mM). Cells were washed using phosphate-buffered saline (PBS) and resuspended in PBS/ 3% bovine serum albumin. Medium B (Fix and Perm, CALTAG) was added to each tube and incubated for 15 min followed by a PBS wash. Apoptosis antibody reagents and controls (IgG1-FITC (BD Biosciences), Bcl-2-FITC (Dako, Denmark), unconjugated IgG1 (BD Biosciences) and Bax (Chemicon, Temecula, CA, USA)) were added with Medium B (Fix and Perm, CALTAG) and incubated for 15 min. PBS was added to each tube and the tubes were mixed and returned to the dark for 5 min. The tubes were centrifuged and paraformaldehyde was added to the tubes with the directly conjugated reagents. To the indirect tubes, freshly diluted goat anti-mouse FITC (Sigma Chemical) was added and incubated for 15 min. The cells were washed in PBS and the pellets were resuspended in paraformaldehyde and stored at 41C until analyzed. FL1 histograms were generated using the appropriate isotype control. A Bax/Bcl-2 ratio was calculated using the percent positive values.
Measurement of mitochondrial membrane potential
The MitoCapture Apoptosis Detection Kit (Calbiochem, San Diego, CA, USA) was used to measure disruption of mitochondrial membrane potential per the manufacturer's recommendations. The MitoCapture cationic dye exhibits distinct red fluorescence in healthy cells in contrast to green fluorescence in cells undergoing apoptosis.
Immunoblotting
MM cell lines (5-10 Â 10 6 cells per well of a six-well plate) were cultured as described, washed with PBS and lysed with buffer (50 mM Tris, 150 mM NaCl, 1% NP-40 and freshly added 2 mM sodium orthovanadate, 5 mM NaF, 5 mM EDTA, 1 mM PMSF, 5 mg/ml leupeptin, 5 mg/ml aprotinin). Lysate protein levels were quantified using the bicinchoninic protein assay (Pierce, Rockford, IL, USA). Lysates were resolved by sodium dodecyl sulfatepolyacrylamide gel electrophoresis and transferred to nitrocellulose (BioRad, Hercules, CA, USA). Proteins were detected using primary and secondary antibodies from Cell Signaling Technology (Beverly, MA, USA) following the manufacturer's instructions. Protein-antibody complexes on the blots were visualized using ECL and Hyperfilm (Amersham, Arlington Heights, IL, USA). Blots were stripped and reprobed with antiactin antibody (Abcam, Cambridge, UK) to confirm equivalent protein loading and transfer. 19, 20 For the caspase inhibition experiments, cells were incubated for 1 h with 20 mM ZVADfmk (Calbiochem), followed by treatment with ABT-737 (10 mM) for the times indicated in the respective experiments. For each experiment caspase inhibition was confirmed by immunoblotting for caspase 3 and poly(ADP-ribose) polymerase (PARP).
RNA isolation and quantitative real-time PCR
Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. Complementary DNA (cDNA) was synthesized using 1 mg total RNA in a Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics, Indianapolis, IN, USA) as per the manufacturer's instructions. PCR was performed using the LightCycler FastStart DNA Master SYBR Green I kit (Roche) with the following parameters: preincubation at 951C for 10 min followed by cycling for 10 s at 951C, 5 s at 591C and 18 s at 721C. Primers used were as follows: Mcl-1 forward, CGCCATCATG TCGCCCGAAGA; Mcl-1 reverse, GTTTGTTACGCCGTCGCTG AA; glyceraldehyde-3-phosphate dehydrogenase (GAPDH) forward, ACCACAGTCCATGCCATCAC; GAPDH reverse, TCCAC CACCCTGTTGCTTGTA. The PCR was stopped when one sample reached plateau. Samples were run on an agarose gel and expression levels were measured using densitometry relative to GAPDH using an AlphaImager 3400 and AlphaEase software (Alpha Innotech Corporation, San Leandro, CA, USA).
Isobologram analysis
The interaction between ABT-737 and other drugs was analyzed using the CalcuSyn software program (Biosoft, Ferguson, MO, USA). This program is based upon the Chou-Talalay method, which calculates a combination index (CI), and analysis is performed based on the following equation:
, where (D)1 and (D)2 are the doses of drug 1 and drug 2 that have x effect when used in combination, and (Dx)1 and (Dx)2 are the doses of drug 1 and drug 2 that have the same x effect when used alone. 21 Data from the MTT viability assay were expressed as the fraction of cells killed by the individual drug or the combination in drug-treated cells compared with untreated cells. A CI of 1.0 indicates an additive effect, whereas CI values below 1.0 indicate synergism.
Results
ABT-737 treatment results in the dose-and time-dependent death of MM cell lines
The impact of ABT-737 on MM cell viability was evaluated by culturing several MM cell lines with a range of drug concentrations based upon effectiveness in other biological systems. ABT-737 was cytotoxic to RPMI 8226, OPM-1, OPM-2, U266 and MM1.S cell lines as well as the IL-6-dependent cell line KAS-6/1 (Figure 1a) . Toxicity in these cell lines was dose dependent and IC 50 values of approximately 5-15 mM were obtained. MM cell lines resistant to commonly used therapeutic agents, including Dox40 (doxorubicin-resistant), LR5 (melphalan-resistant) and MM1.R (dexamethasone-resistant) were also found to be sensitive to ABT-737 in a dose-dependent manner (Figure 1b 
ABT-737 induces apoptosis of MM cells in a dose-and time-dependent manner
We expected that ABT-737 would influence apoptotic pathways and therefore evaluated the induction of apoptosis in MM cell lines. After MM1.S MM cells were incubated with ABT-737 (10 mM) for 0-24 h the percentage of cells undergoing apoptosis was examined using Annexin V/PI staining and flow cytometry. A dose-dependent elevation in apoptotic and necrotic tumor cells was observed ( Figure 2a) . As shown in Figure 2a , a timedependent increase in apoptosis was also observed. To understand the pathways by which ABT-737 induces apoptosis in MM cells, we examined the activation of caspase cleavage cascades in multiple cell lines. Cells were treated with ABT-737 (10 mM) over the indicated time periods and downstream mediators of cellular apoptosis were evaluated by immunoblotting. Figure 2b illustrates the caspase 3, caspase 8, caspase 9 and PARP cleavage events in MM1.S cells associated with initiation of apoptosis.
ABT-737 effectively induces apoptosis of primary MM cells BM cells from MM patients were also treated with ABT-737 to examine cytotoxicity in primary MM cells. Freshly isolated cells were treated with 5 and 10 mM concentrations of ABT-737 for a period of 36-48 h and cell apoptosis was measured using Apo 2.7 staining of the CD38/CD45 plasma cell compartment.
Primary MM cells were variably sensitive to ABT-737, with induction of apoptosis in 20-90% of tumor cells from different patients with MM (Figure 3a) . No significant increase in the percentage of apoptotic cells was observed in most of the patient samples at a 10 mM dose compared to that obtained with 5 mM. Flow cytometry evaluation of the Bcl-2/Bcl-xL inhibition in multiple myeloma MP Kline et al CD38/CD45 patient plasma cell compartment also indicated that ABT-737 was effective in stimulating apoptosis in both the CD45-negative and CD45-positive compartments, although the CD45-positive cells appear to be affected disproportionately as indicated by their disappearance after treatment (Figure 3b ). ABT-737 treatment results in inversion of the Bax/Bcl-2 ratio followed by mitochondrial membrane depolarization and caspase activation in MM cells. Given the potential targets of ABT-737, we examined the effect of ABT-737 upon MM cell apoptosis signaling mechanisms by measuring the ratio between pro-and antiapoptotic molecules in the MM cells. MM1.S cells were treated with ABT-737 (10 mM) for up to 4 h and the levels of Bax (proapoptotic) and Bcl-2 (antiapoptotic) proteins were determined in addition to the Bax/Bcl-2 protein ratio. Figure 4a demonstrates a time-dependent increase in the Bax/ Bcl-2 ratio following treatment with ABT-737. This was paralleled by a time-dependent loss of mitochondrial membrane potential (Figure 4b ). Figure 4b shows a time-dependent decrease in red fluorescence following treatment of MM1.S cells with ABT-737 (10 mM), indicating increasing loss of mitochondrial membrane potential and loss of dye aggregation in the mitochondria. These changes are followed by increased cleavage of caspases 8, 9 and 3 (Figure 4c-e) .
ABT-737 impacts proliferation and survival signals in MM cells
We also examined the effects of ABT-737 upon proliferation and survival signals known to be important in MM cells. MM1.S cells 
ABT-737 exerts synergistic cytotoxicity when combined with other MM drugs
We also examined the ability of ABT-737 to enhance the activity of other commonly used MM drugs. Potent synergy was seen when ABT-737 was combined with dexamethasone as shown in Figure 6a . The presence of synergy was confirmed by the CI values of o1, when evaluated by the Chou Talalay method using Calcusyn software (Figure 6b ). However, no synergy was observed when ABT-737 was combined with either doxorubicin or Velcade at the concentrations tested.
Discussion
MM remains incurable with the current therapeutic approaches, many of which are not necessarily targeted towards the abnormalities that drive the plasma cell clone. 3 As in most cancers, the normal mechanisms of programmed cell death appear to be dysfunctional in the malignant plasma cells. [22] [23] [24] While all of the changes that lead to this phenotype are not clearly understood, available studies would lead us to believe that overexpression of some of the antiapoptotic proteins clearly play a role in disease. How the commonly described genetic events in MM lead to these alterations at the protein level still needs to be elucidated.
While MM cells do not usually have a translocation (such as in follicular lymphomas) that directly leads to increased expression of Bcl-2, elevated levels of this antiapoptotic protein have been reported in malignant plasma cells in MM.
6-8 In Studies have correlated increased expression of these proteins to enhanced tumor cell survival and drug resistance in vitro and in vivo. [9] [10] [11] [12] 25, 26 Our own studies have shown elevated levels of Bcl-2 family member proteins (Bcl-2, Bcl-xL and Mcl-1) in most of the MM cell lines (data not shown). In addition, in vivo studies have demonstrated spontaneous plasma cell tumors in mice with lineage-specific overexpression of Bcl-2 and Bcl-xL, especially when associated with other facilitating mutations like that of c-Myc. 15 Mcl-1 expression in MM cells has been related to survival in patients with MM. 27 The MM growth factors IL-6, Bcl-2/Bcl-xL inhibition in multiple myeloma MP Kline et al APRIL, BAFF and VEGF signal through their respective receptors to modulate the expression of Bcl-2 family proteins such as Bcl-2, Mcl-1 and Bcl-xL. In addition to the antiapoptotic members, the proapoptotic members of the Bcl-2 family including Bax, Bad, Bak and Bik play a role in the survival of MM cells. Studies have suggested a decreased expression of many of these proapoptotic members in malignant plasma cells, which along with increased expression of the antiapoptotic members leads to perturbation of the ratio between prodeath and prosurvival molecules and decreased apoptosis of the MM cell. 18 Inhibition of antiapoptotic Bcl-2 family proteins would be expected to favor programmed cell death of the malignant MM clone and hence represents a valid therapeutic target. In fact, in vitro studies using another small molecule Bcl-2 inhibitor HA14-1 have demonstrated that Bcl-2 inhibition has a synergistic effect on the antimyeloma activity of proteasome inhibitors and flavopiridol. 29, 30 Among the greatest barriers to interfering with protein-protein interaction in the cell are the need for a high degree of binding affinity as well as specificity of the inhibitors and the ability of the molecules to get into the cell. ABT-737 is essentially a designer molecule that has been developed through screening of a library of small molecules by the process of 'SARS by NMR'. 31 It has very high affinity (K i p1 nM) and specificity for the hydrophobic BH3-binding groove on Bcl-2, Bcl-xL and Bcl-w with much less affinity to other homologous proteins such as Mcl-1. ABT-737 has demonstrated significant in vitro activity against lymphoid cell lines as well as small cell lung cancer cell lines and primary cancer cells from patients. 17 ABT-737 has also been shown to induce regression of established lung cancer tumors in mouse models. Here we demonstrate potent antimyeloma activity of ABT-737 in MM cell lines and patient-derived primary MM cells. Several MM cell lines, including a cell line dependent upon IL-6, are killed by ABT-737 at a median concentration of 5-15 mM. This is relevant since IL-6-dependent cell lines have been shown to have survival pathways independent of the Bcl-2 family members. 32 More importantly, cell lines known to be resistant to the commonly used MM drugs are also killed by the drug at similar concentrations, reflecting the ability to overcome conventional drug resistance. Given the variation in drug sensitivity observed with the different cell lines, we examined if there was a correlation between drug sensitivity and the expression of Mcl-1, which is known to be a survival factor for MM cells. 26, 27, [33] [34] [35] Indeed, there was a correlation between the Mcl-1 expression and the proportion of viable cells after 48 h incubation with 5 mM ABT-737. While relatively high expression of Mcl-1 has been seen in most MM cells, we do not believe that this will represent a problem since higher doses of the drug were able to overcome the protective effect. This also forms the rationale for evaluating ABT-737 with other agents known to decrease Mcl-1 levels. It is clear in MM that the marrow microenvironment, especially the stromal cells and endothelial cells, plays an important role in the survival of tumor cells. It is believed that most of these effects are mediated through cytokines such as IL-6, VEGF and IGF-1, which regulate the expression of Bcl-2 family proteins. Hence it is important that ABT-737 is able to kill MM cells in the presence of stromal cells and when grown in the presence of these cytokines. We confirmed the ability of ABT-737 to kill MM cells even when they are cultured in these conditions, albeit at slightly higher concentrations.
We observed potent cytotoxic effects of ABT-737 on patientderived primary MM cells, although there was some variation in terms of sensitivity. We do not have Mcl-1 expression data for the primary patient cells to examine if a correlation exists between drug effectiveness and Mcl-1 levels. The ability of ABT-737 to kill primary tumor cells from a majority of the patients, many of whom had relapsed disease, is of utmost significance from a clinical translation standpoint. In a limited number of patients, we examined if ABT-737 had a differential effect on the MM cell subsets based on their CD45 expression. CD45 expression on MM plasma cells is heterogeneous and has biological and prognostic significance. [36] [37] [38] The CD45-positive subset is believed to include the proliferative subset of plasma cells, and the ability to deplete this compartment has potential therapeutic significance. The suggestion of increased sensitivity among the CD45 þ MM cells is intriguing and needs further exploration.
ABT-737 activates the cleavage of caspase 8 as well as caspase 9. Given the suggested mechanism of action of ABT-737, it is quite possible that cleavage of caspase 8 is a secondary event. Using flow cytometry, we have demonstrated a time-and dose-dependent induction of apoptosis in MM cells following treatment with the drug that is further confirmed by the cleavage of caspase 3 and PARP. Evaluation of Bax and Bcl-2 expression in MM cell lines following treatment with ABT-737 demonstrated time-and dose-dependent (data not shown) increases in MM cell Bax/Bcl-2 ratio. ABT-737 has been shown to behave in a similar manner to the sensitizing BH3 proteins such as Bad, which binds to the antiapoptotic Bcl-2 family members and prevents them from sequestering the activating BH3 proteins Bid and Bim. 17, 18 In accordance with this proposed mechanism, ABT-737 has not been shown to be able to directly release cytochrome c from purified mitochondrial preparations. 17 ABT-737 inhibits the protective effect of Bcl-2 as well as Bcl-xL, an effect that is dependent upon Bax or Bak. Given the involvement of the mitochondrial pathway of apoptosis, we examined the effect of ABT-737 on mitochondrial membrane potential. Using a flow cytometry based methodology that employs a fluorescent dye, we were able to show changes in the mitochondrial membrane potential early after treatment with ABT-737.
ABT-737 impacts proliferation and survival pathways that are critical for MM cells. ABT-737 reduced the cellular levels of Mcl-1 in MM cells even in the presence of exogenous IL-6. Since caspase-mediated cleavage of Mcl-1 has been described as one of the mechanisms for downregulation of Mcl-1 in cells undergoing apoptosis, we specifically examined this. 39 Inhibition of the caspase activity with the pan-caspase inhibitor ZVAD fmk had only a partial effect on the changes observed with Mcl-1 following treatment with ABT-737. Hence it is likely that mechanisms other than caspase-mediated cleavage are responsible for the downregulation of Mcl-1 observed here. These changes are likely at post-transcriptional level since we did not observe any changes in the Mcl-1 transcript levels following treatment with ABT-737. Given the fact that ABT-737 is not known to bind to Mcl-1, it is possible that this is a secondary event following disruption of the mitochondrial function and cellular energy balance given the relatively short half-life of Mcl-1. However, we believe that downregulation of Mcl-1 probably plays an important role in enhancing the cell death seen with MM cells since Mcl-1 has been shown to be a critical survival factor for MM. 27, 40 Similarly, we observed timedependent dephosphorylation of P-Akt and P-STAT3 in MM cells as well as in IL-6-stimulated cultures. It is likely that these results do not represent specific targeting of these signaling proteins by ABT-737, but reflect an ATP-depleted cellular state as a result of disrupted mitochondrial function. However, given the importance of the PI3K/Akt and JAK/STAT pathways in the survival and proliferation of MM cells, these changes are likely to further contribute to tumor cell death.
Given the ability of Bcl-2 family members to enhance drug resistance in MM cells, as well as the reported ability of the ABT-737 to enhance the activity of cisplatin, paclitaxel and radiation in other tumor cells, 17 we examined combinations of ABT-737 with commonly used MM drugs. We were able demonstrate potent synergy with dexamethasone. In conclusion, we have shown that ABT-737 has significant activity against MM cell lines and patient-derived primary MM cells in vitro. It is able to overcome resistance to conventional antimyeloma agents, suggesting a different mechanism of action that may complement these therapies. Additionally, it appears to be able to overcome resistance offered by elements of the tumor microenvironment. Collectively, these results support further evaluation of this agent in the clinical setting, either alone or in combination with other therapies.
